What is Vaccinex Debt-to-Equity?
Vaccinex's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.22 Mil. Vaccinex's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.03 Mil. Vaccinex's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-2.31 Mil.
Vaccinex's debt to equity for the quarter that ended in Dec. 2023 was -0.11.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Vaccinex's Debt-to-Equity or its related term are showing as below:
VCNX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.35 Med: -0.16 Max: 0.09
Current: -0.11
During the past 8 years, the highest Debt-to-Equity Ratio of Vaccinex was 0.09. The lowest was -0.35. And the median was -0.16.
Vaccinex Debt-to-Equity Historical Data
The historical data trend for Vaccinex's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaccinex Debt-to-Equity Chart
|
Vaccinex Annual Data
|
|
Trend |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
- |
-0.35 |
0.05 |
0.09 |
-0.11 |
|
Vaccinex Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.09 |
0.18 |
-0.87 |
-0.08 |
-0.11 |
Competitive Comparison of Vaccinex's Debt-to-Equity
For the Biotechnology subindustry, Vaccinex's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaccinex's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaccinex's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Vaccinex's Debt-to-Equity falls into.
Vaccinex Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Vaccinex's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Vaccinex's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaccinex (Vaccinex) Business Description
Traded in Other Exchanges
N/A
Address
1895 Mount Hope Avenue, Rochester, NY, USA, 14620
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.
Executives
| Van Strydonck, Gerald E. |
director |
1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620 |
| Maurice Zauderer |
director, 10 percent owner, officer: President and CEO |
1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620 |
| Albert Friedberg |
director, 10 percent owner |
|
| Jacob B. Frieberg |
director |
1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620 |
| Elizabeth E. Evans |
officer: Chief Operating Officer |
C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620 |
| Robert Scala |
officer: Chief Commercial Officer |
1895 MT HOPE AVENUE, ROCHESTER NY 14620 |
| Chrystyna Bedrij Stecyk |
director |
1895 MT. HOPE AVENUE, ROCHESTER NY 14620 |
| Vaccinex, Inc. |
director |
1895 MOUNT HOPE AVE, ROCHESTER NY 14620 |
| Jeff Goater |
director |
C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Bala S Manian |
director |
1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043 |
| Barbara Yanni |
director |
1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406 |
| Alejandro M. Berlin |
director |
1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620 |
| John E. Leonard |
officer: SVP, Development |
1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620 |
| Ernest S. Smith |
officer: SVP, Research & CSO |
1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620 |
| Raymond E. Watkins |
officer: SVP & Chief Operating Officer |
1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620 |
Vaccinex (Vaccinex) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VCNX has been successfully added to your